Olaparib and Radiotherapy in Head and Neck Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 36
Summary
- Conditions
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Laryngeal Cancer Stage II
- Laryngeal Cancer Stage III
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02229656
- Collaborators
- AstraZeneca
- Investigators
- Principal Investigator: Marcel Verheij, MD, PhD The Netherlands Cancer Institute